IOBT

Insider Trades

Name	Value	Action	Price	Current Price
Hunter HeidiDirector $21k15k shares BuyMay 30, 2025 $1.39 --
Ahmad Qasim IftikharChief Medical Officer $27k31.4k shares BuyDec 23, 2024 $0.847 --
Smith Devin WhittemoreGeneral Counsel $9.7k12k shares BuyDec 23, 2024 $0.81 --
Sullivan AmyChief Financial Officer $8.5k10.3k shares BuyDec 23, 2024 $0.8276 --
Zocca Mai-BrittDirector, Officer: Chief Executive Officer $10k12.5k shares BuyDec 23, 2024 $0.8096 --
Novo Holdings A/S10 Percent Owner $31k23.5k shares SellJul 26, 2024 $1.31 --

News

defenseworld.netIO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analystsdefenseworld.netApr 18

defenseworld.netAnalysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33defenseworld.netMar 27

Trade IOBT

About IO Biotech, Inc.

IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.

CEO: Mai-Britt Zocca
IPO Date: Nov 5, 2021

Market Data

Open: $0.0152
High: $0.0168
Low: $0.0082
Volume: 3.1M
Avg Volume: 20M
52W High: $2.79
52W Low: $0.0123

Valuation

Market Cap: $886k
Enterprise Value: $-28M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-82M
Revenue: $0
Net Income: $-95M
Cash: $60M
Debt: $1.9M

Events

EarningsMay 13

EPS est. -0.1